

Europe Pharmaceuticals Market Size and Forecast (2021 - 2031)

<https://marketpublishers.com/r/E095849A77EDEN.html>

Date: March 2026

Pages: 287

Price: US\$ 3,450.00 (Single User License)

ID: E095849A77EDEN

Abstracts

The European pharmaceuticals market is projected to grow significantly, reaching an estimated value of approximately US\$ 446.9 billion by 2031, up from US\$ 317.3 billion in 2024. This growth trajectory indicates a compound annual growth rate (CAGR) of 5.0% from 2025 to 2031, reflecting the market's robust potential.

Executive Summary and Market Overview

The European pharmaceuticals market is divided into several key regions, including Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. The growth of this market can be attributed to several factors, including a well-established healthcare infrastructure and increasing investments in research and development. Europe is home to many leading pharmaceutical and biotechnology companies that are dedicated to developing innovative treatments for various diseases, particularly chronic conditions such as cancer.

The prevalence of chronic diseases is a significant driver of pharmaceutical demand in Europe. According to the World Health Organization (WHO), as of July 2024, diabetes has emerged as one of the most prevalent chronic conditions in the region, affecting approximately 64 million adults and nearly 300,000 children and adolescents.

Alarmingly, WHO estimates that one in three individuals with diabetes remains undiagnosed, and many do not achieve their treatment goals. With an aging population and rising obesity rates, projections suggest that by 2045, one in ten Europeans could be living with diabetes. Furthermore, Europe bears the highest global burden of type 1 diabetes. In 2022, the WHO reported over 4.4 million new cancer cases and nearly 2 million cancer-related deaths in Europe, underscoring the urgent need for effective pharmaceutical interventions.

The market is poised for continued expansion, particularly with advancements in immunotherapy and the development of new vaccine technologies. The European pharmaceuticals market stands as one of the largest and most dynamic globally, driven

by factors such as an aging population, a rising demand for innovative treatments, and progressive regulatory frameworks.

Strategic Insights

Market Segmentation Analysis

The European pharmaceuticals market can be segmented based on various criteria:

By Molecule Type: The market is divided into Small Molecule and Biological/Biosimilar Products, with Small Molecule products holding the largest market share in 2024.

By Indication: This includes segments for Metabolic Diseases, Cancer, Immunology, Respiratory Disorders, Cardiovascular Disorders, Neurology Disorders, Rare Diseases, and others, with Cancer being the leading segment in 2024.

By Product Type: The market is categorized into Branded and Generic products, where Branded products dominate.

By Drug Type: The market is further divided into Prescription and Over-the-Counter (OTC) drugs, with Prescription drugs holding the largest share.

By Distribution Channel: This includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, with Hospital Pharmacies leading in market share.

Market Outlook

The European pharmaceuticals market presents vast opportunities across various dimensions, driven by strong manufacturing capabilities, potential for market expansion, technological advancements, and economic contributions. The industry is undergoing a technological revolution, with significant progress in gene therapy, preventive medicine, and digital health technologies. These innovations are paving the way for biotech firms and AI-driven drug discovery, which are expected to transform patient care and treatment methodologies.

The economic impact of the pharmaceutical sector is substantial, supporting millions of jobs globally. The industry not only creates direct employment but also stimulates indirect job creation in related sectors. This highlights the potential for investment in workforce development and supply chain optimization, which can further enhance economic growth.

Moreover, artificial intelligence (AI) is revolutionizing pharmaceutical manufacturing and

research and development, leading to increased efficiency and cost savings. AI solutions can significantly reduce labor costs and enhance operational efficiencies, thereby optimizing logistics and production processes. The integration of AI in drug discovery is also shortening development timelines, allowing for faster and more effective drug development.

Country Insights

The European pharmaceuticals market is further segmented by country, with the Rest of Europe holding the largest market share in 2024. Countries such as Norway, Denmark, Sweden, Poland, Switzerland, Ukraine, Romania, Belgium, and the Czech Republic are key contributors to market growth, characterized by strong healthcare systems and substantial investments in biotechnology. The Netherlands and Belgium are also central to the EU's healthcare landscape, witnessing rapid advancements in pharmaceutical research.

The increasing prevalence of chronic diseases in these regions is expected to drive pharmaceutical demand. For instance, Eurostat data indicates that cancer accounted for over 26% of total deaths in several EU countries, highlighting the urgent need for effective pharmaceutical solutions. Companies like AstriVax Therapeutics in Belgium are at the forefront of developing innovative therapies, such as DNA-based immunotherapies for chronic diseases.

Company Profiles

Key players in the pharmaceuticals market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, and many others. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and deliver innovative solutions to consumers.

Contents

1. INTRODUCTION

- 1.1 Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macroeconomic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country-level data:
- 3.3 Assumptions and Limitations

4. PHARMACEUTICAL MARKET LANDSCAPE

- 4.1 PEST Analysis
- 4.2 Regulatory Landscape
 - 4.2.1 Europe
- 4.3 List of Key Suppliers:
- 4.4 Average selling Price:
- 4.5 Sourcing Strategy:
- 4.6 Market Entry Barriers in the Global Pharmaceutical Market:
- 4.7 Top 10 Blockbuster Drugs Facing Patent Expiry in the Next 5 Years with Revenue Data and Market Impact:

5. EUROPE PHARMACEUTICAL MARKET – KEY MARKET DYNAMICS

- 5.1 Europe Pharmaceutical Market – Key Market Dynamics
- 5.2 Market Drivers
 - 5.2.1 Rising Global Disease Burden and Increasing Demand for Innovative Treatments

- 5.2.2 Expanding Global Access to Medicines and Growing Emerging Markets
- 5.3 Market Restraints
 - 5.3.1 Regulatory Pressures and Market Shifts
- 5.4 Market Opportunities
 - 5.4.1 Harnessing Innovation, AI, and Market Expansion
- 5.5 Future Trends
 - 5.5.1 Regional Power Shifts, Supply Chain Diversification, and Regulatory Evolution
- 5.6 Impact of Drivers and Restraints:

6. PHARMACEUTICAL MARKET – EUROPE ANALYSIS

- 6.1 Europe Pharmaceutical Market Revenue (US\$ Billion), 2021–2031
- 6.2 Europe Pharmaceutical Market Forecast Analysis

7. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY MOLECULE TYPE

- 7.1 Small Molecule
 - 7.1.1 Overview
 - 7.1.2 Small Molecule: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)
- 7.2 Biological and Biosimilar Products
 - 7.2.1 Overview
 - 7.2.2 Biological and Biosimilar Products: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY INDICATION

- 8.1 Metabolic Diseases
 - 8.1.1 Overview
 - 8.1.2 Metabolic Diseases: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)
- 8.2 Cancer
 - 8.2.1 Overview
 - 8.2.2 Cancer: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)
- 8.3 Immunology
 - 8.3.1 Overview
 - 8.3.2 Immunology: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.4 Respiratory Disorder

8.4.1 Overview

8.4.2 Respiratory Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.5 Cardiovascular Disorder

8.5.1 Overview

8.5.2 Cardiovascular Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.6 Neurology Disorder

8.6.1 Overview

8.6.2 Neurology Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.7 Rare Disease

8.7.1 Overview

8.7.2 Rare Disease: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

8.8 Others

8.8.1 Overview

8.8.2 Others: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

9. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY PRODUCT

9.1 Branded

9.1.1 Overview

9.1.2 Branded: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

9.2 Generic

9.2.1 Overview

9.2.2 Generic: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

10. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY TYPE

10.1 Prescription

10.1.1 Overview

10.1.2 Prescription: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

10.2 OTC Drugs

10.2.1 Overview

10.2.2 OTC Drugs: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

11. EUROPE PHARMACEUTICAL MARKET ANALYSIS – BY DISTRIBUTION CHANNEL

11.1 Hospital Pharmacies

11.1.1 Overview

11.1.2 Hospital Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

11.2 Retail Pharmacies

11.2.1 Overview

11.2.2 Retail Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

11.3 Online Pharmacies

11.3.1 Overview

11.3.2 Online Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

12. EUROPE PHARMACEUTICAL MARKET – COUNTRY ANALYSIS

12.1 Europe

12.1.1 Europe Pharmaceutical Market – Revenue and Forecast Analysis – by Country

12.1.1.1 Europe Pharmaceutical Market – Revenue and Forecast Analysis – by Country

12.1.1.2 United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

12.1.1.2.1 United Kingdom: Europe Pharmaceutical Market Share – by Molecule Type

12.1.1.2.2 United Kingdom: Europe Pharmaceutical Market Share – by Indication

12.1.1.2.3 United Kingdom: Europe Pharmaceutical Market Share – by Product

12.1.1.2.4 United Kingdom: Europe Pharmaceutical Market Share – by Type

12.1.1.2.5 United Kingdom: Europe Pharmaceutical Market Share – by Distribution

Channel

12.1.1.3 Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

12.1.1.3.1 Germany: Europe Pharmaceutical Market Share – by Molecule Type

12.1.1.3.2 Germany: Europe Pharmaceutical Market Share – by Indication

- 12.1.1.3.3 Germany: Europe Pharmaceutical Market Share – by Product
- 12.1.1.3.4 Germany: Europe Pharmaceutical Market Share – by Type
- 12.1.1.3.5 Germany: Europe Pharmaceutical Market Share – by Distribution

Channel

12.1.1.4 France: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

- 12.1.1.4.1 France: Europe Pharmaceutical Market Share – by Molecule Type
- 12.1.1.4.2 France: Europe Pharmaceutical Market Share – by Indication
- 12.1.1.4.3 France: Europe Pharmaceutical Market Share – by Product
- 12.1.1.4.4 France: Europe Pharmaceutical Market Share – by Type
- 12.1.1.4.5 France: Europe Pharmaceutical Market Share – by Distribution Channel

12.1.1.5 Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

- 12.1.1.5.1 Italy: Europe Pharmaceutical Market Share – by Molecule Type
- 12.1.1.5.2 Italy: Europe Pharmaceutical Market Share – by Indication
- 12.1.1.5.3 Italy: Europe Pharmaceutical Market Share – by Product
- 12.1.1.5.4 Italy: Europe Pharmaceutical Market Share – by Type
- 12.1.1.5.5 Italy: Europe Pharmaceutical Market Share – by Distribution Channel

12.1.1.6 Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

- 12.1.1.6.1 Spain: Europe Pharmaceutical Market Share – by Molecule Type
- 12.1.1.6.2 Spain: Europe Pharmaceutical Market Share – by Indication
- 12.1.1.6.3 Spain: Europe Pharmaceutical Market Share – by Product
- 12.1.1.6.4 Spain: Europe Pharmaceutical Market Share – by Type
- 12.1.1.6.5 Spain: Europe Pharmaceutical Market Share – by Distribution Channel

12.1.1.7 Switzerland: Pharmaceutical Market – Revenue, 2021 - 2031 (US\$ Billion)

- 12.1.1.7.1 Switzerland: Europe Pharmaceutical Market Share – by Molecule Type
- 12.1.1.7.2 Switzerland: Europe Pharmaceutical Market Share – by Indication
- 12.1.1.7.3 Switzerland: Europe Pharmaceutical Market Share – by Product
- 12.1.1.7.4 Switzerland: Europe Pharmaceutical Market Share – by Type
- 12.1.1.7.5 Switzerland: Europe Pharmaceutical Market Share – by Distribution

Channel

12.1.1.8 Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

12.1.1.8.1 Rest of Europe: Europe Pharmaceutical Market Share – by Molecule Type

- 12.1.1.8.2 Rest of Europe: Europe Pharmaceutical Market Share – by Indication
- 12.1.1.8.3 Rest of Europe: Europe Pharmaceutical Market Share – by Product
- 12.1.1.8.4 Rest of Europe: Europe Pharmaceutical Market Share – by Type

12.1.1.8.5 Rest of Europe: Europe Pharmaceutical Market Share – by Distribution Channel

13. COMPETITIVE LANDSCAPE

13.1 Company Market Share Analysis

14. INDUSTRY LANDSCAPE

14.1 Overview

14.2 Expansion

14.3 New Product Development

14.4 Merger and Acquisition

14.5 Partnerships

14.6 Other Business Strategies

15. COMPANY PROFILES

15.1 Johnson & Johnson

15.1.1 Key Facts

15.1.2 Business Description

15.1.3 Products and Services

15.1.4 Financial Overview

15.1.5 SWOT Analysis

15.1.6 Key Developments

15.2 Pfizer Inc

15.2.1 Key Facts

15.2.2 Business Description

15.2.3 Products and Services

15.2.4 Financial Overview

15.2.5 SWOT Analysis

15.2.6 Key Developments

15.3 Merck & Co Inc

15.3.1 Key Facts

15.3.2 Business Description

15.3.3 Products and Services

15.3.4 Financial Overview

15.3.5 SWOT Analysis

15.3.6 Key Developments

- 15.4 Eli Lilly and Co
 - 15.4.1 Key Facts
 - 15.4.2 Business Description
 - 15.4.3 Financial Overview
 - 15.4.4 SWOT Analysis
 - 15.4.5 Key Developments
- 15.5 Bristol-Myers Squibb Co
 - 15.5.1 Key Facts
 - 15.5.2 Business Description
 - 15.5.3 Products and Services
 - 15.5.4 Financial Overview
 - 15.5.5 SWOT Analysis
 - 15.5.6 Key Developments
- 15.6 ESTEVE
 - 15.6.1 Key Facts
 - 15.6.2 Business Description
 - 15.6.3 Products and Services
 - 15.6.4 Financial Overview
 - 15.6.5 SWOT Analysis
 - 15.6.6 Key Developments
- 15.7 UCB SA
 - 15.7.1 Key Facts
 - 15.7.2 Business Description
 - 15.7.3 Products and Services
 - 15.7.4 Financial Overview
 - 15.7.5 SWOT Analysis
 - 15.7.6 Key Developments
- 15.8 Teva Pharmaceutical Industries Ltd
 - 15.8.1 Key Facts
 - 15.8.2 Business Description
 - 15.8.3 Products and Services
 - 15.8.4 Financial Overview
 - 15.8.5 SWOT Analysis
 - 15.8.6 Key Developments
- 15.9 Hikma Pharmaceuticals Plc
 - 15.9.1 Key Facts
 - 15.9.2 Business Description
 - 15.9.3 Products and Services
 - 15.9.4 Financial Overview

- 15.9.5 SWOT Analysis
- 15.9.6 Key Developments
- 15.10 Viatris Inc
 - 15.10.1 Key Facts
 - 15.10.2 Business Description
 - 15.10.3 Products and Services
 - 15.10.4 Financial Overview
 - 15.10.5 SWOT Analysis
 - 15.10.6 Key Developments
- 15.11 AstraZeneca Plc
 - 15.11.1 Key Facts
 - 15.11.2 Business Description
 - 15.11.3 Products and Services
 - 15.11.4 Financial Overview
 - 15.11.5 SWOT Analysis
 - 15.11.6 Key Developments
- 15.12 Sanofi SA
 - 15.12.1 Key Facts
 - 15.12.2 Business Description
 - 15.12.3 Products and Services
 - 15.12.4 Financial Overview
 - 15.12.5 SWOT Analysis
 - 15.12.6 Key Developments
- 15.13 GSK Plc
 - 15.13.1 Key Facts
 - 15.13.2 Business Description
 - 15.13.3 Products and Services
 - 15.13.4 Financial Overview
 - 15.13.5 SWOT Analysis
 - 15.13.6 Key Developments
- 15.14 F. Hoffmann-La Roche Ltd
 - 15.14.1 Key Facts
 - 15.14.2 Business Description
 - 15.14.3 Products and Services
 - 15.14.4 Financial Overview
 - 15.14.5 SWOT Analysis
 - 15.14.6 Key Developments
- 15.15 Novartis AG
 - 15.15.1 Key Facts

- 15.15.2 Business Description
- 15.15.3 Products and Services
- 15.15.4 Financial Overview
- 15.15.5 SWOT Analysis
- 15.15.6 Key Developments
- 15.16 AbbVie Inc
 - 15.16.1 Key Facts
 - 15.16.2 Business Description
 - 15.16.3 Products and Services
 - 15.16.4 Financial Overview
 - 15.16.5 SWOT Analysis
 - 15.16.6 Key Developments

16. APPENDIX

- 16.1 Glossary of Terms
- 16.2 About The Insight Partners

List Of Tables

LIST OF TABLES

- Table 1. Europe Pharmaceutical Market Segmentation
- Table 2. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)
- Table 3. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Molecule Type
- Table 4. Table: Top-Selling Drugs in 2021
- Table 5. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Indication
- Table 6. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Product
- Table 7. Key brands facing patent expirations
- Table 8. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Type
- Table 9. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Distribution Channel
- Table 10. Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion) – by Country
- Table 11. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type
- Table 12. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication
- Table 13. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Product
- Table 14. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type
- Table 15. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel
- Table 16. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type
- Table 17. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication
- Table 18. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Product
- Table 19. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 20. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 21. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 22. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 23. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Product

Table 24. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 25. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 26. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 27. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 28. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Product

Table 29. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 30. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 31. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 32. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 33. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Product

Table 34. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 35. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 36. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 37. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 38. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Product

Table 39. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 –

2031(US\$ Billion) – by Type

Table 40. Switzerland: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 41. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Molecule Type

Table 42. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Indication

Table 43. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Product

Table 44. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Type

Table 45. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021 – 2031(US\$ Billion) – by Distribution Channel

Table 46. Company Market Share Analysis

Table 47. Glossary of Terms, Pharmaceutical Market

List Of Figures

LIST OF FIGURES

Figure 1. Europe Pharmaceutical Market Segmentation – Country

Figure 2. PEST Analysis

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Europe Pharmaceutical Market Revenue (US\$ Billion), 2021–2031

Figure 5. Europe Pharmaceutical Market Share (%) – by Molecule Type (2024 and 2031)

Figure 6. Small Molecule: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 7. Biological and Biosimilar Products: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 8. Europe Pharmaceutical Market Share (%) – by Indication (2024 and 2031)

Figure 9. Metabolic Diseases: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 10. Cancer: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 11. Immunology: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 12. Respiratory Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 13. Cardiovascular Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 14. Neurology Disorder: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 15. Rare Disease: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 16. Others: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 17. Europe Pharmaceutical Market Share (%) – by Product (2024 and 2031)

Figure 18. Branded: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 19. Generic: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 20. Europe Pharmaceutical Market Share (%) – by Type (2024 and 2031)

Figure 21. Prescription: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 22. OTC Drugs: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 23. Europe Pharmaceutical Market Share (%) – by Distribution Channel (2024 and 2031)

Figure 24. Hospital Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 25. Retail Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 26. Online Pharmacies: Europe Pharmaceutical Market – Revenue and Forecast, 2021–2031 (US\$ Billion)

Figure 27. Europe Pharmaceutical Market Breakdown, by Key Countries, 2024 and 2031 (%)

Figure 28. United Kingdom: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

Figure 29. Germany: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

Figure 30. France: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

Figure 31. Italy: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

Figure 32. Spain: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

Figure 33. Switzerland: Pharmaceutical Market – Revenue, 2021 - 2031 (US\$ Billion)

Figure 34. Rest of Europe: Europe Pharmaceutical Market – Revenue and Forecast, 2021– 2031 (US\$ Billion)

I would like to order

Product name: Europe Pharmaceuticals Market Size and Forecast (2021 - 2031)

Product link: <https://marketpublishers.com/r/E095849A77EDEN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E095849A77EDEN.html>